BlackRock Inc. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$10,959,880
-13.7%
9,288,034
+3.1%
0.00%
Q2 2023$12,707,010
+128.4%
9,012,064
+142.9%
0.00%
Q1 2023$5,564,368
+25.7%
3,709,578
-2.0%
0.00%
Q4 2022$4,427,060
+5.8%
3,783,812
+2.1%
0.00%
Q3 2022$4,186,000
-29.5%
3,704,387
-1.4%
0.00%
Q2 2022$5,934,000
-60.7%
3,755,757
-61.7%
0.00%
Q1 2022$15,106,000
-38.4%
9,809,123
-2.0%
0.00%
-100.0%
Q4 2021$24,521,000
+13.8%
10,008,510
+17.0%
0.00%0.0%
Q3 2021$21,550,000
-11.5%
8,551,700
+0.1%
0.00%0.0%
Q2 2021$24,338,000
+320.4%
8,539,530
+246.6%
0.00%
Q1 2021$5,789,000
+105.5%
2,463,489
+53.9%
0.00%
Q4 2020$2,817,000
+89.1%
1,600,822
+0.6%
0.00%
Q3 2020$1,490,000
+7.4%
1,590,865
-0.2%
0.00%
Q2 2020$1,387,000
-77.1%
1,594,577
-78.2%
0.00%
Q1 2020$6,068,000
-6.5%
7,327,331
+0.5%
0.00%
Q4 2019$6,490,000
-9.1%
7,291,981
+0.0%
0.00%
Q3 2019$7,143,0007,289,5420.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders